Novo Nordisk Pharmatech launches TrypsiNNex®
Today marks an important milestone at Novo Nordisk Pharmatech as we announce the launch of TrypsiNNex® – a new recombinant enzyme in the company portfolio. This product represents a key part of our growth strategy in the specialty enzymes sector for pharmaceutical manufacturing. TrypsiNNex® is a sustainable, animal-free trypsin product that will enable the production […]
We will attend BPI US 2024
We are thrilled to announce our attendance at the upcoming BioProcess International Congress, which will take place September 24-26 at Hynes Convention Center in Boston! We will showcase one of our key specialities, Recombinant Insulin, at booth 814. Approved by the FDA and EMA, our animal-free Insulin is a vital ingredient in over 100 therapeutic […]
Novo Nordisk Pharmatech is investing 1.5 billion Danish kroner in a new factory in Køge
In order to meet significantly higher demand from Novo Nordisk A/S for raw materials for the production of medicines to fight chronic diseases, Novo Nordisk Pharmatech A/S is building a new factory at Ådalen 16 in Køge. In March 2023, Novo Nordisk Pharmatech announced the purchase of a 47,000 m² site in Køge, with the […]
New distribution partnership in Europe
Actylis and Novo Nordisk Pharmatech announce a strategic partnership for the distribution of Benzalkonium Chloride in targeted European countries.
We are presenting at World Vaccine Congress
Join us at the most important vaccine event of the year – the World Vaccine Congress in Washington on April 2-4! Are you looking for reliable partners to improve your vaccine production system? Look no further. We are here to show you how we have helped numerous vaccine developers with our top-quality products. Join us […]
We are attending BPI Europe 2024
We are pleased to announce our attendance at the upcoming BPI Europe congress, taking place April 9-12 in Vienna. We’ll be showcasing one of our products for the biomanufacturing industry, our Recombinant Insulin, at booth number 240. Approved by the FDA and EMA, our insulin is a key ingredient in over 100 therapeutic drugs, revolutionizing healthcare […]
Novo Nordisk Pharmatech Annual Report 2023
In many ways, 2023 has been a transformational year where we made significant progress on our Novo Nordisk Pharmatech growth strategy. Our revenue grew significantly to 880 MDKK in net sales and landed 47% higher than 2022 reflecting a good year across all products, and on top of that, we have brought three new products […]
100 years of Novo Nordisk Insulin
Actylis and Novo Nordisk Pharmatech announce a strategic partnership for the distribution of Benzalkonium Chloride in targeted European countries.
We expand the production
Actylis and Novo Nordisk Pharmatech announce a strategic partnership for the distribution of Benzalkonium Chloride in targeted European countries.
How does Recombinant Insulin differ from animal-derived insulin
Actylis and Novo Nordisk Pharmatech announce a strategic partnership for the distribution of Benzalkonium Chloride in targeted European countries.
